Blue background design

Pipeline

Aldeyra is a well-capitalized biotechnology company with a broad immunology pipeline.

Reproxalap

(ophthalmic solution)
Option agreement w/AbbVie

Dry Eye Disease

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

Reproxalap

(ophthalmic solution)
Option agreement w/AbbVie

Allergic Conjunctivitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-629

(oral administration)

Moderate Alcoholic Hepatitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-629

(oral administration)

Sjögren-Larsson Syndrome

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-248

(oral administration)

Atopic Dermatitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-743

(oral administration)

Obesity/ Hypertriglyceridemia

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-631

(intravitreal injection)

Dry Age-Related Macular Degeneration / Geographical Atrophy

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-2191*

(intravitreal injection)

Retinitis Pigmentosa

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA
*U.S. FDA Orphan-Drug Designated
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors